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ABSTRACT 
 
 
  
Although a great diversity of stem cells can be isolated from the human body for research 
or medical purposes, their applications, ethics, and legalities are still not fully understood by 
many.  This is especially the case for human embryonic stem cells, as there are deep and 
complex ethical implications regarding their isolation from human embryos. In this study, these 
issues are investigated as an excellent example of the interface between science and society.  It is 
of the utmost importance that these potentially life-saving techniques and their legalities across 
the globe be understood by society to make educated decisions about their use. 
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PROJECT OBJECTIVES 
 
 
 The ultimate goal of this IQP report is to provide a cohesive and up-to-date summary of 
the advancements and controversies of stem cell research and the important impacts this novel 
biological technology has had on society.  Chapter-1 serves to introduce the basics of these 
unique cells by describing their classifications and potencies, as well as discussing different 
types of stem cells isolated from numerous parts of the body. The purpose of Chapter-2 is to 
examine the various applications of these stem cells in medical treatments by examining trials 
involving both human and animal models. Chapter-3 changes the focus from biology and instead 
outlines the ethical concerns associated with embryonic stem cell research and the positions of 
the five major world religions on the topic. The intent of Chapter-4 is to similarly describe the 
current legal policies on this research declared by governments in both the United States and 
abroad. This IQP is concluded with a statement from both authors which summarizes the 
authors’ perceptions of the stem cell debate including the ethical and legal concerns.   
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Chapter-1:  Stem Cell Types 
Emily Domain 
 
What Are Stem Cells? 
 Stem cells are a unique type of cell that forms the basis of the development, growth and 
survival of a living organism. Though the term is often used to describe controversial embryonic 
stem cells, there are many different types of stem cells, classified by their original location 
and/or method of formation.  All types share the same basic characteristics that set them apart 
from other types of cells in the body.  The first of these traits is that the stem cell is 
unspecialized; it does not have the ability to do any specific biological function, such as conduct 
neuronal signals or secrete hormones. Instead, the role of the stem cell is to divide and maintain 
its supply until it is needed within the organism. This extended self-renewal is called 
proliferation, and is the second fundamental feature of stem cells. The proliferation of stem cells 
is unique and asymmetric; it allows the body to develop other replacement stem cells along with 
more specialized cells to replace damaged or aging tissue.  When a new specialized cell is 
required, a series of extracellular chemical signals coaxes a stem cell to transform into the 
required type of cell (Stem Cell Basics, 2009). This process, known as differentiation, is the 
quality most intriguing to researchers and physicians, as stem cells could potentially be 
stimulated to differentiate into any type of specialized cell that a sick or injured body could need 
(Newton, 2007, pg. 22). 
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Stem Cell Classification 
 Though all stem cells share these basic characteristics, not every type of stem cell can 
differentiate to the same extent. Therefore, it is convenient to classify stem cells based on their 
plasticity, or their potential to transform into specialized cells that perform a specific biological 
operation (Newton, 2007, pg. 19).  A stem cell that can differentiate into any of the over 200 
kinds of specialized cells in the body, including extra-embryonic tissues, is said to be omnipotent 
or totipotent (Newton, 2007, pg. 4).  An omnipotent stem cell can transform into all cell types in 
the body (including those of a developing embryo) plus the placenta and the supportive placental 
tissues. In mammals, the only truly omnipotent stem cells are those of the newly fertilized egg 
through the 2, 4, or 8-cell stage, which occurs within about 2 days post-fertilization. 
The cells of the pre-implantation embryo continue to 
undergo mitosis and around day-5, they form a 
blastocyst, a hollow ball containing about 100 cells.  At 
this stage, the cells have begun to differentiate into two 
layers: the outer layer of cells is composed of 
trophoblasts (cells of the placenta tissue) and the inner 
cell mass (ICM) composed of a more limited type of 
stem cell described as pluripotent. Pluripotent stem cells 
can become any type of cell in the body originating 
from the “three primary germ layers which are normally 
established during gastrulation of the embryo” (Chamany, 2004, pg. 13). These germ layers, the 
ectoderm, the mesoderm, and the endoderm, are formed after the implantation of the blastocyst 
in the uterine wall, when the pluripotent stem cells in the inner cell mass organize themselves 
Figure-1: Photograph of a Human Blastocyst 
with Evident Trophoblasts and Inner Cell 
Mass (ICM). (Conaghan, 2001) 
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into three distinct layers of cells (Stem Cell Basics, 2009). The ectoderm eventually forms the 
skin, nerves and mucus glands; the mesoderm yields the blood, bones and muscle; and the 
endoderm gives rise to the pancreas, liver, and other internal organs. Thus, a pluripotent stem 
cell can become any specialized cell in the body that is not part of the placental tissue or the 
reproductive organs, which are formed by another collection of cells called primordial germ 
cells. Embryonic stem (ES) cell research, promising yet controversial, is based upon these 
pluripotent stem cells (Chamany, 2004, pg. 2-3). 
 Outside the realm of embryonic development, there also exists a variety of stem cells in 
the adult body which are classified as multipotent. These “adult stem cells” are more limited in 
their ability to differentiate, as they can give rise to cells in only one of the three primary germ 
layers (Chamany, 2004, pg. 13). For example, stem cells in the blood (hematopoietic stem cells) 
can differentiate into any red or white blood cell or platelet, but are usually limited to only these 
blood-related cells (Domen et al., 2006, pg. 14). Cells of this potential, called progenitor cells, 
have also been discovered in many places in the human body, including the brain, liver and 
pancreas (Chamany, 2004, pg. 5).  The investigation and use of adult stem cells, or somatic stem 
cells, does not carry as much controversy as embryonic stem cell research, but their medical uses 
are also more limited due to their restricted differentiation potential (Newton, 2007, pg. 19).  
 There is also a class of adult stem cell, called a precursor cell, which is described as 
unipotent. These cells can only differentiate into one type of specialized cell and are often 
intermediates in the differentiation of a multipotent stem cell into a specialized cell (Newton, 
2007, pg. 122).  Unipotent skin and hair precursor cells, for instance, result from the mitosis of a 
multi-potent skin stem cell during differentiation (Cotsarelis, 1991, pg. 82). 
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A Brief History of Stem Cell Science 
 Prior to the dramatic increase in stem cell discoveries in the mid-20
th
 century, scientists 
had speculated the existence of such an entity since the 1700’s. Interest in the regeneration of 
limbs and other structures in plants and animals launched the scientific investigation of stem 
cells.  Early biologists sought to understand why simple plants and other organisms “knew” how 
to regenerate tissues, while the highly developed human body could not (Newton, 2007, pg. 6). 
This ability was not hypothesized to be attributed to a unique cell until the early 1900’s, when 
Alexander Maximow, a Russian hematologist, applied the idea of regeneration to blood cells in 
the human body.  Maximow posited that a “common stem cell of different blood elements” was 
responsible for the development and replacement of all types of blood cells. This idea was later 
supported in 1960 by the research of Ernest Armstrong McCulloch and James Edgar Till at the 
Ontario Cancer Institute who found that mice injected with bone marrow developed nodules on 
their spleens (the location of blood formation in mice) whose presence corresponded with the 
amount of marrow injected (Newton, 2007, pg. 8).  The team discovered that these nodules were 
made of a single repeating “colony forming unit”- the hematopoietic stem cell predicted by 
Maximow.  
 Another early discovery that led to the development of the idea of stem cells was the 
existence of the teratoma.  Originally known simply as “monstrosities”, teratomas are large 
tumors that consist of clumps of cells from all three primary germ layers. These monstrous 
looking tumors have the potential to contain characteristics of any specialized cell in the body 
(Newton, 2007, pg. 9).  For example, in the accidental discovery that led embryologist Leroy 
Stevens to research these bizarre tumors, Stevens dissected a laboratory mouse with a teratoma 
that “contained both skeletal and cardiac cells, the latter beating in unison, as they would in a 
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mature heart” (Newton, 2007, pg. 11).  Stevens’ goal was then to observe the earliest step in the 
formation of teratomas in mice, and in 1964 identified the cause as an abnormal sperm cell 
growing in the genital ridge of an embryo. He called this cell a “pluripotent embryonic stem cell” 
and went on to demonstrate that some cells in the teratoma could proliferate indefinitely and 
remain undifferentiated (Newton, 2007, pg. 12).  When these embryonic carcinoma (EC) cells 
were injected into the organs of a mouse, Stevens observed that they would quickly differentiate 
and again form a mature teratoma (Newton, 2007, pg. 13-14).  Further research by Beatrice 
Mintz and Karl Illmensee in the 1970’s showed that EC cells extracted from cancerous teratomas 
and transplanted into normal developing mouse blastocysts became fully integrated into the 
tissue of the developing mouse, indicating that a stem cell’s environment can influence its 
differentiation (Chamany, 2004, pg. 4). 
These experiments supported the existence of a cell with the unique characteristics of a stem cell, 
but it would be another decade before scientists physically isolated and cultured a stem cell.  In 
1981, the team of Martin Evans and Matthew Kaufman from the University of Cambridge 
successfully extracted embryonic stem cells from the inner cell mass (ICM) of a mouse 
blastocyst (Evans and Kaufman, 1981; Newton, 2007, pg. 14).  They also demonstrated the 
ability of these extracted murine ES cells to proliferate indefinitely and differentiate in vitro, a 
breakthrough that began the modern era of stem cell research and application (Chamany, 2004, 
pg. 4). 
Types of Stem Cells 
Embryonic Stem Cells 
 Embryonic stem (ES) cells are “invariably derived from the ICM of 5-day-old embryos 
(blastocysts) or fetal gonadal tissue” (Alison, 2005, pg. 2).  At this stage of embryogenesis, the 
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embryo has not yet implanted in the uterus, and the cells of the inner cell mass (ICM) have not 
yet begun to differentiate into the primary germ layers (Yu, 2006, pg. 1).  The blastocyst is only 
composed of about 100 cells at this point, 30-40 of those being the pluripotent stem cells of the 
ICM.  These cells begin to differentiate soon after the implantation of the embryo, but can be 
held in a state of indefinite proliferation if isolated and cultured correctly in vitro (Yu, 2006, pg. 
3).  These embryonic stem cells are considered the most plastic of all stem cells (except the 
totipotent cells of the early blastomere), and thus have the most to offer stem cell biologists (Vats 
et al., 2005, pg. 83).  Their great promise is matched by their great controversy, as the 
unavoidable destruction of the embryo during the removal of the ICM raises ethical questions 
about the formation and destruction of life (discussed in Chapter-3). As a result, most 
governments have strict regulations on the operation and funding of embryonic stem cell 
research projects (discussed in Chapter-4). 
 The embryonic stem cell was the first type of stem cell to be isolated, as demonstrated by 
the mouse model of Evans and Kaufman in 1981.  The isolation of the first human ES cell, after 
years of ethical objections and scientific dilemmas, was 
performed independently by two teams: one under the 
direction of John Gearhart at Johns Hopkins University 
(Shamblott et al., 1999), and another under James A. 
Thomson at the University of Wisconsin (Thomson et al., 
1998; Newton, 2007, pg. 16).  Gearhart and coworkers 
extracted pluripotent primordial germ cells from the 
immature gonads of aborted fetuses that later were found to have less desirable proliferation 
properties than true ES cells (Chamany, 2004, pg. 14).  Alternatively, the team under the 
Figure-2: Embryonic Stem Cell. 
(Embryonic, 2012) 
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direction of James Thomson used “leftover” fertilized eggs from in vitro fertilization (IVF) 
techniques to isolate ES cells (Newton, 2007, pg.  17).  IVF involves the fertilization of an 
oocyte (egg cell) by a sperm cell outside the body, the growth of the embryo to the blastocyst 
stage, and for reproductive purposes the implantation of the blastocyst into the uterus for 
gestation.  To increase the probability of creating a healthy blastocyst, this therapeutic technique 
requires the fertilization of numerous oocytes at a time. The remaining embryos are then frozen 
to be preserved for further implantations (Chamany, 2004, pg. 16).  It was from these “extra” 
embryos that the first human embryonic stem cell was isolated. 
 IVF clinics are still the primary source of human ES cells for therapy and research, 
through the donation of their surplus blastocysts with donor consent.  In 2006, there were an 
estimated 400,000 spare embryos in storage from IVF procedures in the United States.  Of these, 
88.5% were claimed for use in further implantation, while 2.8% were donated to scientific 
research, a total of approximately 11,000 embryos (Yu, 2006, pg. 3).  However, the most 
promising embryos created through IVF are used in implantation, leaving the more unsound and 
frail embryos for donation.  Of these donations, it is estimated that only 275 blastocysts are 
healthy enough to be used for scientific inquiry, as the chance of blastocyst formation in humans 
is only 1 in 18, and the freeze/thaw cycle tends to destroy cell membranes and other proteins.  
For this reason, in some countries outside the United States where laws allow embryos to be 
created solely for research purposes, IVF clinics and research institutes have begun seeking the 
help of volunteer oocyte donors. These are women who undergo the IVF procedure and donate 
their embryos to researchers rather than having them implanted for gestation (Chamany, 2004, 
pg.  17).  
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Parthenote Stem Cells 
 Embryonic stem cells isolated from leftover IVF blastocysts are not ideal for therapeutic 
use due to their ethical issues. Also, since the blastocyst is a hybrid of male and female genetic 
donors, the stem cells will also be a combination of genetic material and would be subject to 
resistance in the recipient body.  To circumvent this issue, scientists have been investigating the 
use of artificial parthenogenesis to create homozygous ES cells (Kim et al., 2007, pg. 1). 
Parthenogenesis is a form of asexual reproduction in which an unfertilized egg duplicates its own 
genetic material and begins to divide, developing into an embryo. In nature, this process occurs 
in some insect species to create large amounts of worker insects, but it does not normally occur 
in mammals. Parthenogenesis can be artificially induced in mammals by an electric pulse to an 
unfertilized egg, mimicking the charge brought upon by the flow of calcium ions during normal 
fertilization (Chamany, 2004, pg. 18).  The ES cells isolated from this blastocyst will “express 
only one of two sets of parental histocompatibility antigens” and therefore run less risk of 
rejection in the body, especially if implanted into the same donor female (Kim et al., 2007, pg. 
1).  The embryos produced by artificial parthenogenesis cannot fully develop with only one set 
of genetic material, so some scientists believe this avoids the moral dilemma over the destruction 
of embryonic life (Chamany, 2004, pg. 18). 
 
Somatic (Adult) Stem Cells  
 A large variety of adult stem cells are found throughout the body.  These multipotent 
cells are “capable of producing a limited range of differentiated cell lineages appropriate to their 
location” (Alison, 2005, pg. 6).  The role of these stem cells is to maintain the health and vitality 
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of the tissue in which they are located.  Stem cells can remain in an undivided state (quiescent) in 
the “stem cell niche” for long periods of time until they are needed in the body (Stem Cell 
Basics, 2009).  The stem cell niche is the protective microenvironment of the adult stem cells, 
generally a part of the tissue that undergoes the least amount of stress.  The stem cell niche is 
thought to control much of stem cell behavior, via the use of “cells and extracellular matrix 
components” (Alison, 2005, pg. 9).  To date, somatic stem cells have been identified in the 
human “brain, bone marrow, peripheral blood, blood vessels, skeletal muscle, skin, teeth, heart, 
gut, liver, ovarian epithelium, and testis” (Stem Cell Basics, 2009). 
 The first direct evidence of the stem cell came from adult hematopoietic (blood) stem 
cells.  In the groundbreaking work of Till and McCulloch 
in the 1960’s, the team observed tumors in mice injected 
with irradiated bone marrow, which were formed by a 
single colony-forming unit: a hematopoietic stem cell 
(Newton, 2007, pg. 8). They deemed this cell to be 
pluripotent, but by today’s standards it is considered 
multipotent; it is the source of all blood cells in the body, but 
generally cannot differentiate beyond this type of cell (Domen et al., 2006, pg. 15). The majority 
of the hematopoietic stem cells (HSCs) in humans are located in the bone marrow, but this 
location is used more infrequently in medicine due to the pain and cost of the isolation 
procedure.  In the late 1980’s, HSCs were also isolated from the blood of the umbilical cord, a 
tissue that is normally discarded after the birthing process. This tissue is rich in HSCs, which 
appear to have greater proliferation potential than those isolated from adult bone marrow 
(Domen et al., 2006, pg. 22). 
Figure-3: Hematopoietic Stem 
Cells.  (Hematopoietic, 2011) 
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 Human bone marrow also contains another type of stem cell called mesenchymal stem 
cells (MSC).  These cells have the ability to differentiate into all connective tissue cell types, 
including bone, cartilage, and tendons (Baksh, 2004, pg. 305).  The earliest demonstration of the 
existence of these cells was in 1961 by A. J. Friedenstein, who showed that bone marrow cells 
can undergo osteogenesis, producing bone cells rather than the expected blood cells (reviewed in 
Friedenstein et al., 1976; Baksh, 2004, pg. 302).  MSCs have since been isolated from 
“trabecular bone, adipose tissue, synovium, skeletal muscle, lung, deciduous teeth, and umbilical 
cord cells” (Baksh, 2004, pg. 304).  An interesting aspect of these cells is that they appear to 
exist in a variety of different potentials, including a state of pluripotency which is usually only 
found in embryonic stem cells (Baksh, 2004, pg. 306).  Although further differentiated 
mesenchymal cells are more commonly found in the body, it has been demonstrated that some 
MSCs can form cells in all three primary germ layers (Baksh, 2004, pg. 308).  However, it is 
estimated that there exists only one MSC for every 34,000 differentiated somatic cells in the 
body, and the probability of that cell being completely undifferentiated is smaller yet (Beyer and 
Meirelles, 2008, pg. 255). 
 Another type of somatic stem cell is responsible for an organ long known to regenerate in 
humans: the skin.  The first direct evidence of this epithelial skin cell came in 1981 by the 
application of a thymidine label to basal (skin) cells (Bickenbach, 1981).   J. R. Bickenbach 
demonstrated that a small group of basal label-retaining cells (not undergoing DNA replication 
or cell division) carried this label for 240 days, an extremely long cell cycle for skin. Upon 
examination of these cells, they were observed to be “small, contain few organelles, occupy a 
fixed position in the tissue architecture, and are clonogenic [colony-forming] in vitro”, all 
characteristics of a somatic stem cell (Cotsarelis, 1991, pg. 83).  Epithelial skin cells are found in 
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the epidermis and the hair follicle bulge, and give rise to all the precursor cells for skin and hair 
(Cotsarelis, 1991, pg. 81-82). These stem cells have also been found in the cornea, and there is 
evidence that corneal tissue can be coaxed to differentiate into skin cells (Dhouailly, 1991, pg. 
87). Approximately 10% of basal cells are epithelial stem cells, and it is believed that they are 
the only type of cell that lasts the entire life of the epidermis (Bickenbach, 1991, pg. 84). 
 The discovery of adult stem cells in other organs has forced scientists to reevaluate the 
regeneration potential of organs once thought to be “terminally differentiated”, such as the heart 
and the brain (Beltrami et al., 2003, pg. 763).  The first 
evidence for neuronal stem cells was observed in 1989 
(Temple, 1989), and by the mid 1990’s, it was discovered 
that the brain can regenerate neurons under conditions of 
stress via a neural stem cell, contradicting the original 
assumption that the brain had no regenerative potential. 
These stem cells can give rise to neurons and the supportive 
brain cells, oligodendrocytes and astrocytes (Rebuilding… 2009).  Neural stem cells are 
particularly exciting to scientists in the area of drug delivery and gene therapy, as they could 
guide therapeutic agents directly to target areas in the brain and other tissues (Müller et al., 
2006).  In 2003, Antonio Beltrami and his team at New York Medical College demonstrated that 
the adult heart also has regenerative potential. They successfully isolated and cultured in vitro 
the first cardiac stem cell from an adult rat. These cells can differentiate into any type of cardiac 
cell: myocytes, smooth muscle, and endothelial cells (Di Felice et al., 2009, pg. 449-450). 
 Somatic stem cells have also been isolated from many other locations in the body, and 
some show promise of pluripotentiality. In the adult liver, hepatocytes are normally non-
Figure-4: Immunofluorescence 
Staining of a Neural Stem Cell.  
(Unique Neuroepithelial, 2012) 
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proliferative (do not undergo mitosis) but in response to cell loss they enter the cell cycle and 
begin to regenerate liver tissue.  Thus, they can be “regarded as a functional stem cell for the 
liver” (Vats et al., 2005, pg. 87).  Even liposuction waste contains an estimated “50-100 million 
stem cells per 250 g” which can be used to generate fat, bone, and cartilage cells (Alison, 2005, 
pg. 15).  Stem cells have also been extracted from amniotic fluid, which surrounds a developing 
fetus and absorbs the cells that it sheds. These cells are called amniotic fluid-derived stem cells 
(AFS) and have been coaxed to differentiate into cells from all three primary germ layers. These 
cells do not create the full complement of proteins expected from a pluripotent stem cell, and 
consequentially have not been observed to form a teratoma upon injection (Battey, 2006, pg. 83). 
 
Induced Pluripotent Stem Cells 
 Given the limited plasticity of most adult stem cells and the controversy surrounding 
embryonic stem cells, it has been necessary to search for alternative methods of acquiring 
pluripotent stem cells. In 2005, the focus shifted from locating pluripotent stem cells to 
“reprogramming” already differentiated cells back into their stem-like state.  Current research in 
induced pluripotent stem (iPS) cells centers on the isolation of the genes responsible for 
pluripotency and the methods used to introduce them to a differentiated cell. The pioneer in this 
area is Shinya Yamanaka of Japan, who first isolated iPS cells from mice in 2006 (Takahashi et 
al., 2006) and later from humans in 2007 (Takahashi et al., 2007).  In his 2007 work with human 
cells, Yamanaka de-differentiated a human fibroblast (skin cell) by the insertion of just four 
genes: OCT3/4 SOX2, KLF4, and c-MYC.  He did this by introducing an altered retrovirus that 
carried the genes for pluripotency, which were then incorporated in the chromosomes of the 
fibroblast. However, it was found that c-MYC was linked to the formation of tumors, and 
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retroviruses inherently tend to disrupt cancer-inhibiting genes, so biologists also experimented 
with adenoviruses (which do not enter chromosomes) and “piggyBacs”, genetic carriers that can 
leave the chromosome after reprogramming finishes. In 2009, Sheng Ding of the Scripps 
Research Institute began research into the insertion of proteins, rather than the genes that code 
for them, into the somatic cell. He did this by attaching the proteins to the end of a positively 
charged polyarginine molecule, which carries the proteins across the cell membrane. Unlike 
genes which remain in the cell and can become reactivated, these proteins break down rapidly 
and leave behind no genetic material to become cancerous, making them a safer option than gene 
insertion (Aldhous, 2009). 
 
Cloned Stem Cells 
In an attempt to derive ES cells genetically identical to a specific patient and minimize chances 
of immune-rejection, Hwang Woo Suk of South Korea proposed using somatic cell nuclear 
transfer (SCNT) in 2005.  This technique involves the insertion of a nucleus isolated from a 
differentiated adult somatic cell (usually a skin cell) into an enucleated egg (Newton, 2007, pg. 
17).  Factors present in the cytoplasm of the oocyte (egg cell) promote the restoration of the 
pluripotent state of the nucleus, and the embryo divides to the blastocyst stage from which ES 
cells are obtained (Battey, 2006, pg. 87).  This cloned embryo, however, is still subject to the 
debate over the creation and destruction of life (Newton, 2007, pg. 18).  In 2005, the South 
Korean team claimed success with the SCNT approach in humans, but the work was later 
discredited for data fabrication (Hwang et al., 2005). 
A proposed solution to this came in 2006 when Dr. Rudolph Jaenisch at MIT developed altered 
nuclear transfer (ANT), a modification of SCNT that inhibited the gene Cdx2, which is 
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responsible for the implantation of the embryo in the uterus. Technically, this meant that the 
embryo could not give rise to life and thus to some scientists it would avoid the moral and ethical 
objections of normal embryos. However, ANT remains controversial and research has not yet 
progressed outside of mouse studies (Battey, 2006, pg. 84-85). 
 
Proliferation and Differentiation of Stem Cells 
 A single isolated stem cell is of limited use in science and medicine. Instead, the focus is 
on the creation of stem cell lines: a collection of cells derived from the isolated stem cell, which 
can grow and proliferate in vitro and can adopt a variety of cell fates (Chamany, 2004, pg. 13). 
This cell line propagates indefinitely in the correct culture medium, maintaining its “stemness” 
and plasticity until needed. An important aspect of these cell lines is their potential to be patient-
specific, either by the derivation of iPS cells from the patient’s skin cell, or by the use of SCNT 
(not achieved yet in humans).  This would greatly reduce the risk of rejection if the recipient was 
the same as the skin cell donor, as the cells carry the DNA of only the host and the risk of an 
immune reaction is lowered (Chamany, 2004, pg. 6). It is these resulting immune-matched stem 
cell lines that will be used for applications in therapeutic and regenerative medicine.  Lines of 
other stem cell types, unable to be used therapeutically, could be utilized in drug development 
and testing, and inquiries into the nature of embryogenesis (Newton, 2007, pg. 21-22). 
 Another current focus of stem cell research is the creation of an environment that can 
promote either the proliferation or differentiation of a cultured stem cell and its resulting lineage 
(Newton, 2007, pg.  20).  Just as stem cells rely on chemical signals inside their niche in the 
body, stem cells cultured in vitro rely on extracellular proteins, called extrinsic factors, to 
“provide the necessary induction or inhibition signals to promote the adoption of one cell fate 
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versus another” (Chamany, 2004, pg. 4).  Before these signals can be introduced, the stem cells 
need a surface to which they can attach in vitro, called the feeder layer.  
In early ES cell cultures, the cells of this layer (called feeder cells) were irradiated mouse 
embryonic fibroblasts (connective tissue). These provided a proper scaffold and nutrients, but 
some scientists worried about the mixture of animal proteins with the human ES cells, so later 
experiments used irradiated human cells as a feeder layer with some success (Newton, 2007, pg.  
20).  With the feeder layer established, extracellular signals, such as cytokines, growth factors, 
amino acids, proteins, and active ions can be used to influence the mitotic pathway of the cell 
(Vats et al., 2005, pg. 89).  The division of the stem cell can be made to be symmetrical, where a 
stem cell produces two cells of the same kind: either two differentiated daughter cells (clonal 
extinction) or two daughter stem cells (clonal expansion). Stem cells can also divide 
asymmetrically, where a stem cell produces one differentiated daughter cell and one daughter 
stem cell (Newton, 2007, pg. 19; Gordon, 2005, pg. 69).  
The introduction of the correct extrinsic factors can manipulate the stem cells to favor a specific 
mitotic path, like clonal expansion for the development of a stem cell line or clonal extinction for 
differentiation into a tissue, by activating or inhibiting key parts of the cell’s DNA (Newton, 
2007, pg.  13).  An early example of this is the use of leukemia inhibitory factor (LIF) in the late 
1980’s by researchers at the Ludwig Institute for Cancer Research in Australia (Chamany, 2004, 
pg.  4). This protein promotes the proliferation of mouse embryonic stem cells, even in an 
environment that lacks feeder cells (Yu, 2006, pg. 4).  However, it has the opposite effect on 
human ES cells, causing them to rapidly differentiate (Chamany, 2004, pg. 11).  The current goal 
in cell therapy is to identify a definitive set of culture conditions to promote proliferation along 
any differentiation path desired without inducing any genetic mutations (Yu, 2006, pg. 5). 
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Chapter-2:  Stem Cell Applications 
Diego Prentice-Webb 
 
Not only do stem cells serve humans as an important learning device to help better 
advance our knowledge in areas such as embryogenesis, cellular differentiation, and cell repair, 
but they also serve as life-changing medical instruments used by doctors around the world. With 
over a half a century of research already completed on them, doctors have been successful in 
using them to treat genetic disorders such as diabetes and a diverse array of cancers, and have 
changed lives transplanting them into patients who have suffered mechanical or physiological 
damage to their organs and tissues. It is vital that this research continues so that stem cells may 
be exploited to aid patients around the world.  The purpose of this chapter is to describe the 
applications of stem cells for treating several example diseases, as an introduction to their 
benefits to society, which is an important aspect of their ethics. 
By far, the most widely studied stem cell type, the hematopoietic stem cells (HSC), was 
first characterized over 50 years ago in the bone marrow (Till and McCulloch, 1961). Their 
ability to self-renew and differentiate into all types of blood and immune cells led scientists to 
begin investigations on their potential as treatments for irradiated mice with fatally low levels of 
red and white blood cells. Since their discovery, HSCs and many other stem cell types have been 
used in various medical applications including treatments for patients with diabetes and 
leukemia. 
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Diabetes Treatment with Stem Cells 
Currently afflicting roughly 2.8% of the global population (Wild et al., 2004) and 25.8 
million Americans (American Diabetes Association, 2011), diabetes mellitus has been around for 
decades leaving many with no choice but to rely on daily insulin shots and other medications. 
Patients with type 1 diabetes are unable to produce and secrete insulin (a hormone which causes 
liver, muscle and fat tissue to absorb excess glucose from the blood and convert it into glycogen) 
due to an abnormal autoimmune response against the β-cells that normally manufacture it.  The 
lack of insulin causes the patients to have a constantly elevated blood glucose level (BGL) 
leading to hyperglycemias and ketoacidosis if untreated. Similarly, patients suffering from type 2 
diabetes also experience high BGL, but in this case as a result of cells not responding correctly to 
insulin. Treatment options for diabetes vary from a lifetime dependence on insulin injections or 
an insulin pump, to a dangerous pancreatic and/or islet cell transplantation in combination with 
immunosuppressants.  
In the past decade, studies have emerged using both autologous (same individual) and 
allogeneic (histocompatible) stem cells to become functional insulin-secreting cells in patients. 
Initial in vitro studies differentiated pluripotent human embryonic stem (hES) cells into 
embryoid bodies (EB) by suspending them in bacterial-grade petri dishes after disaggregation. 
The cells were then left to spontaneously differentiate into a vast array of cell phenotypes, 
including one similar to (but not identical to) that of β-cells positive for insulin secretion (Assady 
et al., 2001).  Later, variations in the method for inducing functional β-cell analogues from other 
embryonic stem cell lines were developed using transcription factors to aid the differentiation 
and chemical signals which regulate normal pancreas cell formation (Kroon et al., 2008). 
Additionally, phosphoinositide kinase inhibitors were shown to improve the quantity of insulin 
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produced. These differentiated cells led to the successful rescue of non-obese diabetic (NOD) 
scid mice helping to establish normal BGL, suggesting that transplantation of these cells can be a 
potential treatment in vivo (Hori et al., 2002). 
In addition to differentiated ES cells, other types of stem cells also show promise for 
treating diabetes, including stem cells derived from bone marrow.  Hematopoietic stem cells 
(HSCs) have been shown to have the capability to differentiate into insulin-secreting endocrine 
cells when cultured with a high-concentration glucose-containing medium. Once transplanted 
into the kidneys of NOD/scid mice, these cells which also express other pancreas-specific 
transcription factors and proteins other than insulin, successfully mimicked endocrine cells by 
working just like normal islets, maintaining a constant, healthy BGL, and therefore preventing 
hyperglycemia (Oh et al., 2004).  
Despite the success in using stem cells to treat animal models of diabetes, there have been 
some concerns regarding the use of human stem cells in murine studies. For example, in some 
experiments the transplanted differentiated hES cells have caused the growth of teratomas in the 
graft areas (Kroon et al., 2008). It has also been suggested that because the differentiated cells 
are cultured in vitro in a two dimensional space as opposed to natural β-cells which have grown 
in vivo in a microenvironment containing other cell types in a three dimensional space, a poor 
formation of islet of Langerhans can result producing low insulin levels (Guo and Hebrok, 2009). 
Thus, before stem cell treatments and transplantation can be a reality for diabetes patients these 
barriers must be overcome. However, it is important to note that advancements continue in this 
field; there are currently 62 clinical studies across the globe using stem cells to treat both type 1 
and 2 diabetes (National Institute of Health, 2011). 
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Repairing Damaged Heart Tissue with Stem Cells 
 The longest standing culprit of death in America since 1918 is cardiovascular disease 
(CVD) which includes stroke, myocardial infarction (MI), high blood pressure, coronary heart 
disease (CHD), and heart failure. At present, CVD affects an estimated 82,600,000 American 
adults (Roger et al., 2011) and is the cause of more than a third (33.6%) of all mortalities in the 
country in 2007 (Xu, 2010). Complications arise when heart tissue is deprived of oxygen, 
causing cardiac muscle cells (cardiomyocytes) to die, resulting in ventricle wall thinning and 
stretching, an overload of blood flow and pressure and heart failure (Goldthwaite, 2009).  
Repair or regeneration of these lost cardiac cells is therefore vital for a patient to 
successfully recover from CVD. Modern pharmacological and surgical innovations have greatly 
improved in the intervention of patients suffering from acute CVD, but therapies that can 
regenerate lost myocardial (heart muscle) tissue are extremely limited and must be explored. 
Since host cardiomyocytes cannot proliferate fast enough to be used to repair MI, the cells that 
naturally differentiate into myocardial tissue, known as myoblasts, became a key point of interest 
for scientists trying to heal tissue after heart failure.  Myoblasts were initially found to regenerate 
myocardial tissue after transplantation onto areas of infarction in murine models (Murry et al., 
1996) and were later found to do the same in humans; in 2001 the first transplantation of 
autologous myoblasts was performed in tandem with a bypass surgery on a patient with severe 
heart failure caused by extensive myocardial infarction and anterolateral ischemia, providing him 
with improved heart function (Menasché et al., 2001). This novel study encouraged others to 
pursue similar transplant options at it showed that stem cells can serve as a viable treatment 
option for patients with CVD. 
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Currently, in vitro, animal in vivo, and human clinical studies are all being performed to 
understand the efficacy, safety, and mechanism by which diverse forms of stem cells can help 
heal heart tissue after CVD, including but not limited to, mesenchymal stem cells and ES stem 
cells.  At present, the most popular form of stem cell therapy used during in vivo studies is bone 
marrow mononuclear cells. When locally administered to areas of infarction in mice, these cells 
have been shown to spark the development of myocytes and vascular structures in the 
surrounding areas (Orlic et al., 2001). Schächinger et al (2006) are one the few groups that have 
managed to compile a large scale clinical study (more than 200 patients) that uses both negative 
controls (placebos) and positive controls (infusion of stem cells). The team discovered that the 
left ventricular ejection fraction (a measure of the heart’s ability to pump blood out of a ventricle 
per heart beat) was significantly raised in patients receiving intracoronary infusions of BMCs 
compared to patients receiving the placebo treatment, suggesting improved left ventricular tissue 
recovery from MI after treatment with BMCs. 
Due to the immense array of phenotypes that embryonic stem cells can differentiate into, 
similar studies have emerged investigating the viability of human ES cells as a treatment for 
human CVD. Human ES cells have been shown to differentiate in vitro into spontaneously 
beating cardiomyocytes (Kehat et al., 2001) as well as improving cardiac function in post-
infarcted rats (Min et al., 2002).  However, due to the previously mentioned tendency to form 
cancer at the graft site, and their ethical and legal obstacles, there are no ongoing studies using 
ES cells to treat human patients with CVD complications.  
It is evident from the above discussion that stem cell therapies are promising to help aide 
patients who have suffered from CVD, but there is much more to be learned about the specific 
mechanism behind which each unique stem cell type can form and help repair cardiac tissue. In 
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addition, before stem cell therapy for CVD can become a standard clinical practice, more 
information must be brought to light regarding the potential difference of using one stem cell 
type over another, all done using randomized, placebo-controlled trials (the study done by 
Schächinger et al (2006) serves as a great model in respect to this) to remove any uncertainties 
(Boyle, Schulman and Hare, 2006). Regardless of advancements in treatments, the severity and 
frequency of having CVD should not be taken lightly by anyone. To avoid it, everyone should 
regularly exercise, have a healthy diet, and avoid smoking. 
 
Stroke Recovery 
A stroke is a potentially life threatening and life changing attack on the brain which 
occurs when there is an abrupt and severe decrease in oxygen reaching our vital brain cells. This 
deficiency can cause the rapid death of any type of brain cell, and occurs when an artery 
becomes clogged by a blood clot, causing a decrease in blood flow (ischemia, the leading cause 
of stroke) or by an artery rupturing (hemorrhage).  An estimated 795,000 Americans suffer from 
a stroke every year, while more than 137,000 die from it, costing the nation an estimated $73.7 
billion for relevant medical treatments (National Stroke Association, 2010). Since an estimated 
two million brain cells die every minute during a stroke, the most important thing that can be 
done to treat stroke and avoid permanent damage is the immediate transportation of the patient to 
a hospital. Standard clinical practice for ischemic stroke involves the swift activation of the 
physiological process of thrombolysis (the lysis of blood clots) by the administration of a clot 
dissolver drug, such as tissue plasminogen activator (tPA) or aspirin, so that blood flow can be 
restored. Although this treatment has shown to reduce the risk of disability after an attack, it 
must be administered within 3 hours of the stroke, and it can also result in an excess of blood 
flow in the brain which can prove fatal (Wardlaw et al., 2009).  To complicate matters even 
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more, the treatment of hemorrhagic stroke is extremely difficult, so only a handful of patients are 
able receive the dangerous neurosurgery. 
Outside of these therapies, little development in medication for patients has occurred.  
When studying potential treatments in murine models, it is relatively easy to administer 
treatment quickly, while in human practice, the administration of drugs occurs much later 
(Willing et al., 2007).  However, present research is focusing on the safety of administering stem 
cells for treating stroke, helping to regrow brain cells.  It is known that some types of stem cells 
can differentiate into cells that express neuronal proteins found in normal CNS cells (Brazelton 
et al., 2000). Further, studies have shown that transplanted bone marrow cells in rats with 
induced stroke will migrate towards the site of damage which differentiate into cells exhibiting 
marker proteins of astrocytes and oligodendrocytes (Chen et al., 2008). Likewise, the injection of 
green fluorescent protein-tagged hematopoietic stem cells in rats that have undergone induced 
stroke were detected to first migrate to the CNS where they differentiated into microglia-like 
cells resulting in a reduction in infarct volume. The HSCs also translocated to the spleen where 
they were found to counterattack ischemia-mediated effects by increasing proinflammatory 
cytokine and chemokine receptor levels (Schwarting et al., 2008). 
 
Stem Cells and Tissue Engineering 
The basis for tissue engineering has been around for many years, combining molecular 
biology, material science, and engineering.  This field refers to the replacement of damaged or 
lost organs usually by means of donor matrices. Two options can be used when replacing an 
organ: 1) acellular matrices can be implanted which depend on the recipient’s own cells to direct 
tissue growth, and 2) matrices can be implanted that have been seeded with cells. Cells used to 
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populate a matrix can be heterologous (different species), allogenic (same species, different 
individual), or autologous (of the individual), and are traditionally cells that make up the organ in 
question.  Recently surgeons have been looking towards using stem cells as a potent source to 
seed matrices for patients.   
Tracheal removal and repair for patients with malignant or benign tumors is a highly 
limited operation, as only 30% of the total trachea length in children, and up to 6 cm long in 
adults, is considered feasible for removal. Non-biological grafts have been unsuccessful so far, 
proving too complex and lengthy to be a suitable replacement. Tracheal homografts have been 
known to induce long-term stenosis, and have unpredictable growth patterns, so a better strategy 
for transplantation is required. In 2008, a team of surgeons in Spain, led by Dr. Paolo 
Macchiarini, were treating a 30 year old Colombian woman, Claudia Castillo, whose trachea and 
left main bronchus suffered from major damage caused by tuberculosis resulting in severe 
dysphonia (Macchiarini et al., 2008).  A patient suffering from dysphonia has a reduced ability to 
use their vocal organs to produce normal speech or phonation. After several unproductive 
procedures, including the placement and various replacements of a Dumon stent in the patient’s 
left bronchus to try and alleviate her stenosis, a complete replacement of the left main bronchus 
with a bioengineered human trachea was proposed. Their plan was to use autologous stem cells 
harvested from the patient either from the bloodstream or directly from the bone marrow, and 
then grow them in a laboratory and graft them onto the trachea. Unlike conventional organ 
transplants, there is no need for the use of immunosuppressant drugs after using autologous cells.  
This approach is of great importance to the future of transplant operations as it greatly reduces 
the risk of rejection of the new organ due to an immune response.  However, many patients do 
not possess an adequate population of healthy autologous adult stem cells needed to line these 
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organs, which limits the procedure from being available to a wide population of patients. As a 
result, it has been suggested that it may be more beneficial to use human ES cells for the seeding, 
as they remain almost indefinitely in their undifferentiated state, have an enhanced proliferative 
capacity and exhibit greater pluripotency (Metallo et al., 2008). 
Regardless, Dr. Macchiarini and his team planned to use a donor windpipe which had 
been cleaned of all its cells and lined the inner walls of the trachea using the patient’s own 
mesenchymal stem cells harvested from her bone marrow.  A 7 cm trachea was obtained from a 
recently deceased donor and stripped of all connective tissue and HLA antigens. Mesenchymal 
stem cells were obtained from the patient’s bone marrow aspirate, and cultured in DMEM 
containing 10% fetal bovine serum, L-glucose, penicillin, streptomycin, and basic fibroblast 
growth factor for 72 hours.  Chondrocyte differentiation was then induced by methods described 
by Kafienah et al. (2007), the medium was replaced with DMEM containing recombinant human 
transforming growth factor-β 3, recombinant parathyroid hormone-related peptide, 
dexamethasone and insulin, and the cells were incubated for another 72 hours. The internal face 
of the matrix was then seeded with donor epithelial cells while the external surface was 
colonized by differentiated chondrocytes. The characterized matrix was then rotated along its 
longitudinal axis in culture medium for 96 hours before implantation.  
A left posterolateral thoracotomy (fifth intercostals space) was performed, leaving the 
distal trachea and left main bronchus free for Dr. Macchiarini’s team to insert the patient’s new 
trachea. The result was a landmark achievement, as for the first time ever a patient received a 
completely bioengineered organ and recovered fully (Macchiarini et al., 2008). In 2010, the 
procedure was successfully repeated with a 10 year old boy who was born with Long Segment 
Congenital Tracheal Stenosis, a rare condition which leaves the child with an abnormally narrow 
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airway (University College London, 2010). The great strides taken by Dr. Machhiarini and his 
team have paved the way for the future of organ transplantation, and have sprung hope in 
patients requiring donor organs who cannot receive them. Similar organ transplants using 
matrices populated by stem cells should therefore eventually become a viable option for patients 
in the future. 
 
 
Cancer Stem Cells, A Target for the Future? 
To culminate our review of stem cell applications, we move towards using a different 
approach in examining how stem cells can be exploited to help cure disease. In this case, stem 
cells are not being transplanted or used to produce new cells to help cure an ailment, but our 
knowledge of them is being applied to investigate the cause and nature of perhaps the greatest 
weakness of the human cell: cancer. Although it is currently known that both internal factors 
(inherited mutations, weakened immune system, DNA replication errors) and external factors 
(carcinogens, pathogens, radiation) are responsible for transforming cells, the explanation for 
how all these extremely different factors can trigger a cascade reaction that ultimately causes 
multiple mutations leading to an unstoppable force of cell divisions is still not clear.  However, 
after decades of research it is becoming more clear that cancer is a disease resulting from our 
own habits rather than just genetic deformities, as research has shown that up to 90-95% of all 
cancers are a result of environmental factors (see Figure-1), especially tobacco use and poor 
diet. 
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Figure-1:  The  Various Causes of 
Cancer.  (Anand et al., 2008) 
 
 
 
 
 
Regardless of the causing factors, all cells in the human body are vulnerable to becoming 
cancerous, as their DNA is susceptible to genetic mutation whether on the nucleotide level or at 
the chromosomal level. Mutations that cause cancer either change or create novel oncogenes, 
which are genes that code for proteins that normally stimulate cell growth and division, so that 
they are overexpressed producing inappropriate cell reproduction. When the genes that code for 
proteins that try and prevent this excessive cell division by triggering apoptosis (cell death) 
(known as tumor suppressors) become non-functional from mutations, the cell will become 
immortal and tumorigenic also.  
One peculiar and deadly feature of cancer is that it can metastasize or migrate through the 
blood or lymph to another part of the body, and begin to grow there, severely reducing a patients 
expected survival rate. It is difficult to grasp how a small amount of malignant cells can survive 
this highly complex process which requires that the cancer cells free themselves from the 
primary tumor, migrate, exit the circulation, adhere to the foreign tissue, develop a blood supply, 
and finally maintain their growth there. Additionally, scientists have also questioned how cancers 
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of the same type have varying levels of resistance to radiation and chemotherapy, even in early 
stages of tumor progression.  
These queries could be answered with the cancer stem cell (CSC) model.  In 1994, 
Lapidot et al. discovered that a rare subpopulation of stem cell-like cells (only 1 in 250,000 cells) 
found in acute myeloid leukemia (AML) could be harvested and transplanted onto scid-mice, 
growing extensively with a morphology characteristic to that seen in cancer patients. Since then, 
cancer stem cell (CSC) populations have been found in breast cancer (Al-Hajj et al., 2003), brain 
cancer (Galli et al., 2004), prostate cancer (Collins et al., 2005) and pancreatic cancer (Li et al., 
2007) each exhibiting self-renewal, differentiating capabilities, and cell-surface markers seen in 
stem cells, suggesting that they must play some role in tumorigenicity or tumor maintenance. 
When isolated and transplanted into mice, these CSCs have been shown to successfully generate 
tumors with remarkably similar phenotypes seen in patients signifying that they could be tumor 
initiating cells and be responsible for metastasis as they can self-renew without differentiating, 
something normal tumor cells do not possess. Furthermore, these specialized cells have shown 
enhanced resistance to chemotherapeutic agents (Liu et al., 2006) suggesting that cancer’s 
extraordinary ability to resist cell death via therapy may be linked to the number of CSCs present 
in the tumor (Clarke et al., 2006). 
Physicians are given very limited options in how to treat patients with cancer as they are 
left to choose between surgical removal, which may not even fully cure the patient, or using 
radiation treatment or chemotherapy, which can devastate normal tissue and still cause little 
damage to the cancer due to resistance. Thanks to the CSC hypothesis, physicians have now been 
given the opportunity to target new pathways and/or cell surface markers that are unique to CSCs 
which will hopefully prove to be a much better treatment method than existing practices. 
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Whether it is proven that CSCs are indeed the cause of cancer, their potential as targets for drug-
induced destruction is immense. Drug development assays should focus on using CSC lines in 
parallel with accepted cancer cell lines for treatment since it has been shown that the tumors 
initiated by CSCs after transplantation into mice more accurately mimic actual tumors seen in 
patients than some cancer cell lines (Galli et al., 2004). 
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Chapter-3: Stem Cell Ethics 
Emily Domain 
 
The recent advancements in stem cell research have caused a need to reevaluate personal 
and doctrinal convictions worldwide.  A number of oppositional arguments have arisen in the 
past decade, most of them citing evidence for ‘respect of the embryo’ and proposing the 
fundamental question of when life begins (Newton, 2007, pg. 32, 34). This chapter seeks to 
outline the positions of the five major world religions on this question and on embryonic stem 
cell research as a whole.  Other related dilemmas that arise from stem cell research, such as 
cloning, induced pluripotent stem cells and artificial parthenogenesis, will also be addressed. 
 
Embryonic Stem Cell Ethics 
 In the realm of stem cell research, there is little debate over the research and therapeutic 
use of adult stem cells. In fact, all major world religions agree on the use of somatic stem cells, 
as long as the research is dedicated to the relief of human suffering.  The controversy instead 
focuses on the use of embryonic stem cells (ESCs), whose isolation involves the destruction of a 
5 day old blastocyst embryo (Alison, 2005, pg. 2). The destruction of this embryo for research 
purposes results in a profound debate over the rights of the embryo. One's opinion of the proper 
rights granted to this blastocyst depends on that person or system's assumption of the state of the 
pre-implantation embryo at that time. The determination of this state of being as a living entity, a 
ball of tissue cells, or something in between, is driven deeply by one's personal conviction as to 
where and when life begins. This is the belief that also determines where one stands on the 
continuum of support for embryonic stem cell research. 
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 On one end of the spectrum are those individuals who are morally opposed to embryonic 
stem cell research by any means. This can be for a variety of reasons, but the most common is 
the “conceptionalist” view: that a human embryo is a person and should thus be given all the 
rights of a fully developed human being. This viewpoint is based on the conviction that life 
begins at conception, and that the destruction of this being for science is equivalent to murder. 
Those opposed to the scientific destruction of an embryo also cite a modification of the 
conceptualist view called the “potentiality argument”. Supporters of this argument believe that 
since the embryo has the potential to be a human life, it should be considered as such (De Wert 
and Mummery, 2003). They argue that, regardless of whether the blastocysts destroyed in ESC 
research are human life, interfering in the development of the embryo is immoral since it 
prevents the formation of a person (Devolder, 2005, pg. 176).  
 Oppositely, other individuals argue that the embryo deserves no protection at all, and is 
usable for scientific inquiry. In their opinion, the 5 day old blastocyst has not yet attained the 
status of ‘life’ and is a non-person. Its destruction is thus of little or no moral dilemma. To 
support this idea, defenders of this opinion point to the “limited individuality” of the pre-
implantation embryo. Prior to about the 14
th
 day of development, the embryo can split and form 
twins, or two embryos can fuse together. Supporters of this idea argue that the destruction of the 
embryo at day 5 is well within the time that the embryo can alter its nature, and therefore its 
purpose has not yet been established. Another fact used to defend ESC research is that 50-60% 
of pre-implantation embryos are nonviable and cannot form a human being, so their destruction 
should not hypothetically be a moral issue (De Wert and Mummery, 2003). This is not to say that 
all supporters of embryonic stem cell research necessarily view embryonic tissues as disposable, 
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but simply that opinions on the point of the formation of life differ.  It is these different opinions 
that lead to the difference in religious stances on embryonic stem cell research.  
 Of course, the support for embryonic stem cell research is not solely divided into the 
extremes of approval and opposition. There exists a wide spectrum of intermediate viewpoints 
into which most people and religious organizations fall. These factions generally agree that the 
embryo deserves some protection, but not necessarily the same protection given to a full term 
child.  In the religious world, this brings about the question of spiritual development. Religions 
who view spiritual development as a step-wise process, like physical embryogenesis, generally 
condone ESC research up to a certain developmental point. There are also “conditional 
supporters” of inquiry into ESCs: those who condone the use of embryonic stem cells derived 
under certain conditions, but not derived using other conditions. For example, there are those 
who support the use of spare embryos from in vitro fertilization (IVF) clinics, but not the use of 
embryos created specifically for scientific investigation (Devolder, 2005, pg. 167). 
 Ultimately, the question of stem cell ethics can be represented as one’s personal 
conviction on three basic ethical matters. The first is connected to the principle of 
proportionality: does one feel that the potential of these stem cells to benefit the living outweighs 
the destruction of this unborn entity?  This argument is generally connected with one’s opinion 
on the beginning of life as at conception or another developmental stage (Devolder, 2005, pg. 
172).  The second important question is based the slippery-slope argument, which suggests that if 
therapeutic cloning is allowed for the harvesting of stem cells, there is no way to prevent 
reproductive cloning (the creation of living genetically identical individuals). An ethical 
dilemma, reproductive cloning is the application of somatic cell nuclear transfer (SCNT) 
techniques to fertility treatments, resulting in a fully cloned human being. The third fundamental 
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concern in stem cell ethics is based on the principle of subsidiarity. This states that other 
alternatives exist, specifically adult stem cells and induced pluripotent stem cells, and asks 
whether embryonic research should be the scientific focus, or if any other options successfully 
validate the other two basic moral questions (De Wert and Mummery, 2003).  
 
Positions of the Five Major World Religions on Embryonic Stem Cells 
Christianity 
 Among the most adamant opposition of embryonic stem cell research is the Roman   
Catholic Church, which believes that life begins at the moment of conception, thus the 
destruction of the blastocyst in ESC research is equivalent to murder. However, this has not 
always been their view on the beginning of life. Since Christianity is based on Jewish teachings, 
the early Catholic Church originally held the same beliefs as the Jews about the beginning of life: 
that “humanness” is achieved when the fetus is fully developed. The first collection of church 
laws, written in 1140 by the canon lawyer Gratian, stated that abortion was not immoral until the 
fetus was “formed”, or began to resemble a human being. The Church’s current position on the 
beginning of life at conception was implemented in 1854 by the dogma of the Immaculate 
Conception under Pope Pius IX (Newton, 2007, pg. 27-28). This dogma stated that Mary, mother 
of Jesus Christ, was without “original sin” (the human tendency to act immorally) from the 
moment of her conception in the womb, and was thus fit to give birth to the son of God.  The 
church, then, moved to establish conception as the beginning of life (Robinson, 2007). 
 Opponents of stem cells research in the Roman Catholic Church draw many examples 
from the teachings of Pope John Paul II, especially his encyclical Evangelium Vitae. This work 
cites Bible passages to support the idea that life begins at conception. Of these passages, the most 
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influential is Jeremiah 1:5, “Before I formed thee in the belly I knew thee; and before thou 
camest forth out of the womb I sanctified thee.” John Paul cites this passage to say “All human 
beings, from their mothers’ womb, belong to God who 
searches them and knows them, who forms them and knits 
them together with His own hands, who gazes on them when 
they are tiny shapeless embryos and already sees them the 
adults of tomorrow…” (Newton, 2007, pg. 28).  John Paul 
also describes the story of Mary’s visitation with her cousin 
Elizabeth (Figure-1), where in recognition of Mary, 
Elizabeth’s fetus “leap[ed] in her womb”.  John Paul uses 
this as evidence for the sanctity of prenatal life, concluding 
that the destruction of a human embryo for experimentation 
is “a crime against their dignity as human beings, who have 
a right to the same respect owed to a child once born” (Newton, 2007, pg. 28). 
 Other denominations of Christian faith have conflicting viewpoints on stem cell research. 
Orthodox Christianity shares the same opinion as the Roman Catholic Church, that the 
destruction of an embryo is a sin against human life, and is morally and ethically unjustifiable. 
Positions of Protestant denominations vary among the different churches. The first Christian 
faction to take a stand in favor of stem cell research was the United Church of Christ in 2001, 
followed by the Episcopal Church in 2003.  Both denominations have been actively petitioning 
to the US government for legislation to give federal funding to embryonic stem cell projects. 
Alternatively, there are denominations like the Southern Baptist and Lutheran Church of 
Figure-1: Painting of Mary’s Visitation 
with Elizabeth. (Sanzio, 2012, pg. 1520) 
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Missouri, which oppose stem cell research on the basis that an embryo is “totally and fully 
human in every way” (Newton, 2007, pg. 30). 
 
Judaism 
 As Judaism was the precursor to Christianity, it is often surprising to learn that the 
general Jewish stance on embryonic stem cell research is one of support rather than moral 
objection. In fact, all major denominations of Judaism (Orthodox, Conservative, and Reform) 
agree upon this support (Newton, 2007, pg. 31). The reason for this approval of ESC research is 
that the teachings of Judaism argue for a different opinion than Catholic teachings over the 
instant when life begins. Jews carry beliefs from prior to the installment of the Catholic dogma 
of the Immaculate Conception, and maintain that humanness is not attained until the fetus begins 
to resemble a human being. 
 According to the Talmud, the Jewish guide to moral and civil law, human ensoulment 
occurs around day 40 of gestation, and prior to that, the fetus exists “as if it were simply water”. 
As a result, the destruction of the 5-day old blastocyst to isolate stem cells is not a moral 
predicament. After the 40
th
 day of gestation, the fetus is considered “like the thigh of its mother”: 
something that normally would not be removed but can be extracted if it is causing harm. This is 
used to support the Jewish stance on abortion: that the act is considered more like self-injury than 
murder, and is permissible when the fetus poses a threat to the mother. Stem cells extracted from 
fetal tissue aborted under Jewish law can be used for research and to better the already existing 
human population. The Jewish faith also supports the in vitro creation of embryos for research. 
Genetic material and embryos that exist outside the womb are not protected under Jewish law, as 
they are not considered part of the human body until implantation. Since these IVF embryos 
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cannot form a human being outside the womb, they are given even less protection than early in 
vivo embryos, and are able to be used for therapy or research purposes. 
 Jewish faith dictates that the body is an earthly loan from God, and as outlined in the 
Torah, the first five books of the Hebrew bible, there are certain requirements to care for it.  One 
of these requirements is pikuah nefesh, the obligation to preserve human life and health. It is 
considered a “duty to God to develop and use any therapies that can aid us in taking care of our 
bodies, which ultimately belong to God”, including stem cell research. Because of this 
instruction, Judaism views ESC research as a necessity rather than something to be combated 
(Dorff, 2002). 
 
Islam 
 Unlike Christianity or Judaism, the Islamic faith has no specific doctrine concerning stem 
cell research. As Islam is also derived from Judaism, most Muslims share the opinions of the 
Jews, but there is also inner disagreement, as no single teaching unites the Muslim position. The 
moral ethics of embryonic stem cells research must then be inferred by each adherent from the 
Muslim body of principles, the Shari’ah (Frazzetto, 2004). Like the Jewish Talmud, the Shari’ah 
makes a distinction between potential life and actual life. Muslims recognize the value of the 
embryo and consider it to have the potential to become a human being, but do not view it as such 
before birth. For example, Muslim jurists have ruled that if someone attacks a pregnant woman 
and kills her fetus, their punishment will be less severe if the attack takes place within the first 40 
days of pregnancy than if it had progressed to full term. This clearly demonstrates that the 
Islamic conviction is generally that ensoulment occurs around day 40 of embryogenesis. 
 46 
Muslims also recognize the distinction between in vivo and in vitro embryos. They 
believe that since an embryo in vitro lies outside its natural environment and cannot form a 
functional human being, there is nothing morally wrong with its loss for the benefit of humanity. 
Supporters argue that thousands of spare IVF embryos are created and subsequently frozen, only 
to be destroyed eventually anyway.  In the words of Dr. Muzammil Siddiqi of IslamiCity, “If 
these embryos were treated as full human, it would have been forbidden to produce them in 
excess and to destroy them later” (Siddiqi, 2002).  He argues that since the “potential 
humanness” of the embryos is already ignored in their creation, their destruction is not an ethical 
problem. He continues to say “Perhaps if research was limited to using only these already 
existing embryos, it would be more acceptable than if embryos were created and destroyed 
specifically for the sake of acquiring stem cells" (Siddiqi, 2002). 
 
Buddhism 
 The question of stem cell ethics becomes unclear within the context of Buddhism. 
Buddhists do not believe in the idea of the personal self: there is “no act, no actor, and no 
consequences of action”. In the terms of the destruction of embryos for stem cell research, it has 
since become necessary to define personhood to outline ethics. This presents a challenge as 
Buddhists reject the “illusion of self” and strive to transcend it (Hughes, 1995, pg. 6). There are 
no Buddhist teachings directly related to stem cell research, and thus Buddhist opinions tend to 
be split on the matter. This is likely due to two conflicting tenets in Buddhist tradition: ahimsa, 
(the “prohibition against harming or destroying others”) versus prajña (the “pursuit of 
knowledge”) and karua (compassion) (Religious Groups, 2008). 
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 Buddhist opinions on the beginning of life are adapted from classical Hindu teachings 
that preach that the “transmigration of consciousness” during reincarnation occurs at conception. 
However, modern Buddhists argue that spiritual development may mimic physical development 
in the sense that it is a step-wise process. The Buddhist theory of ensoulment is that during 
embryogenesis, the person develops their five skandhas (physical and mental components of 
existence) in order, and the illusion of personhood is not complete until birth (O’Brien, 2011). 
The karmic retribution for the destruction of this embryo brings about a question of the nature of 
Buddhist ethics, and one’s opinion on this matter will also affect their position on stem cell 
research. For example, an absolutist would argue that bad karma will come from the destruction 
of the embryo, no matter the justification, while a utilitarian could view the same situation as 
having positive karmic consequences for the benefits of medical research. An interesting thing to 
note about Buddhism is that, unlike most major religions, it is not “pro-natalist”. It does not see 
family values and reproduction as a religious duty, and Buddhist temples even sell rituals 
intended to be an apology by the parents to an aborted fetus, hoping for a better rebirth for their 
child (Hughes, 1995, pg. 8-10).  
 
Hinduism 
 The Hindu Vedas, the ancient series of Hindu scripture, 
teaches that all life is sacred and this life begins at the moment of 
conception. However, as a people that also believe in reincarnation, 
the Hindus recognize that life and death are inevitably tied.  In fact, 
giving up one’s life for the greater good has traditionally been 
regarded as a sacred act (Bhanot, 2008). There is the traditional 
Figure-2: Dadhichi, a Sage 
from Hindu Mythology. 
(BAPS.org, 2011) 
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story of Dadhichi, a sage from Hindu mythology (Figure-2) who gave up his life so his bones 
could be used to eliminate a demon. Hindu tradition glorifies his actions, and he is seen as a 
model for all Hindus. The question at hand is if the destruction of an embryo for stem cell 
research is equivalent to this act, since the embryo does not have the free will to make its own 
decision.  
 As the Hindu church does not have an official stance on ESC research, the ethics of stem 
cells in Hindu culture depends on one’s opinion of the source and recipients. Most Hindus agree 
that if the stem cells and/or embryos are voluntarily donated then their use is not a moral 
dilemma. It is likened to the donation of the body to medical research, a praiseworthy action in 
Hindu culture. The ethical concerns arise if and when stem cell donation becomes a commercial 
exchange. Another ethical concern important to Hinduism is the availability of the benefits to all 
people, not only those who can afford the expenses of the high-cost technology (Tyagananda, 
2002). 
 
SCNT, iPS, and Parthenogenesis Ethics 
 While embryonic stem cell research has caused religions to reassess their positions on the 
beginning of life and the ethics of abortion and cloning, alternatives to stem cell research have 
also caused their own share of moral dilemmas. 
Opinions are mixed on the relatively new technique of 
creating induced pluripotent stem cells (iPSCs) via gene 
insertion into a somatic cell (Figure-3), SCNT in which 
the nucleus from a skin fibroblast cell is transferred into 
an enucleated egg which is grown to the blastocyst stage Figure-3: A Colony of Induced Pluripotent 
Stem Cells Surrounded by Fibroblasts. 
(Genetics Policy Institute, 2011) 
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from which ES cells are obtained, and parthenotes which are chemically stimulated eggs used to 
provide ES cells. While some view these feats as valid solutions to the destruction of human life, 
others point out that SCNT and parthenotes use new types of embryos.  
For example, in a debate in the Bioethics Forum of the Hastings Center in 2008, both 
sides of the argument can be clearly observed.  The editor of the Hastings Center Report, 
Gregory Kaebnick, speaks for the opposition and argues that cells created by SCNT could be the 
first step in the development of a new type of embryo. His idea comes from the fact that the 
pluripotent cell created through the SCNT technique, the clonote, “looks much like a zygote and 
may well be capable of developing into a baby.”  With respect to iPS cells, genetically induced 
pluripotency was invented to form a stem cell while bypassing the creation of an embryo.  
However, Kaebnick argues that if reprogramming an adult cell through SCNT creates a new type 
of embryo, then reprogramming a cell via gene injection could also possibly create yet another 
new type of embryo still subject to the debate over the rights of the embryo (Kaebnick, 2008). 
 Alternatively, Cynthia Cohen and Bruce Brandhorst of Georgetown University and 
Simon Fraser University, respectfully, argued in their response to Kaebnick that induced 
pluripotent stem cells via gene insertion are not totipotent, and are more like embryonic stem 
cells than an actual embryo. To support this assertion, they describe three properties shared by 
ES cells and iPS cells: a lack of the extracellular layer required for implantation in the uterus, 
small size with a lack of organization like an egg, and no evidence of totipotency.  They argue 
that this tissue lacks the ability to implant and survive in the uterus, and therefore should not be 
considered as life (Cohen and Brandhorst, 2008). 
 With respect to parthenogenesis, the process by which an unfertilized egg is induced to 
begin dividing to form an embryo. This is a natural form of asexual reproduction for certain 
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insects and reptiles, but when induced in humans it results in either a nonviable embryo or a 
tumor. The parthenote is considered unable to progress past the embryo stage, as it is 
“genetically programmed to die early in its development.” However, there is no conclusive 
scientific evidence that the parthenote cannot theoretically form a human being, so this 
hypothetical being is subject to the potentiality argument. Aside from this, whatever abbreviated 
lifespan this defective embryo has is still involved in the debate over the destruction of life 
(Cheshire, 2011). 
 
Chapter-3 Conclusions 
 There is a wide spectrum of ideas on embryonic stem cell ethics, ranging from full 
support to adamant opposition of research. This range is made evident by the dissent both 
between and within the major world religions. The Roman Catholic Church, for example, is a 
staunch opponent of the destruction of embryos for the extraction of stem cells, but other factions 
of Christianity support their use. Other major religions including Judaism and Islam condone the 
use of embryos in research on the basis that life does not begin until the 40
th
 day of pregnancy. 
The religions that do not believe in the “traditional” sense of life and personhood, such as 
Hinduism and Buddhism, do not have official stances on ESC research, so the ethics of the topic 
are at the discretion of the adherent.  As religious opinions are split on the matter pertaining to 
natural embryos, these opinions also diverge on the use of embryos created through IVF and 
other pluripotency-inducing techniques. 
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Chapter-4: Stem Cell Legalities 
Diego Prentice-Webb 
 
 Regardless of their immense potential to benefit society, the study and applications of 
stem cells must be governed and protected by the law to ensure that this controversial research is 
performed in a safe and ethical fashion.  And as is typical for controversial technologies, stem 
cell policies are often strongly influenced by politics, religion, and culture.  The purpose of this 
chapter is to discuss the U.S. stem cell policies, national and state, and describe some key 
international policies. 
The policies that countries maintain to control stem cells vary immensely and are shown 
in Figure-1. The wide variation seen among the countries stems from a spectrum of different 
religious, ethical, and political views making the process behind approving any law very difficult 
and lengthy as it depends on many variables. When law makers discuss stem cells, they tend to 
focus on the source of the cell (embryonic or adult) and the source of money funding the 
research (federal or state) (The Gargoyles, 2005). 
 
 
Figure-1:  Stem Cell Policies Shown by Country. Color code:  "permissive" 
 "flexible"  Restrictive (Hoffman, 2005). 
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Federal Stem Cell Laws in the USA 
Stem cell research in the US has its beginnings rooted earlier than people may actually 
realize, dating back to the 1920s when physicians were attempting to transplant fetal tissue into 
patients suffering from diabetes. Nearly half a century later, and only thirteen years after the 
accidental discovery of stem cells, in 1973 the Supreme Court of the United States deliberated 
the landmark case of Roe vs. Wade (case 410 U.S. 113) which led to the legalization of abortion. 
Consequently, lawmakers began to ask themselves to what extent could aborted fetuses be used 
for in scientific research as they would now become more available to scientists. Shortly after, on 
July 12, 1974 the 93
rd
 Congress passed the first law regarding stem cells stating that the federal 
government would not fund any research involving fetal tissue until guidelines are defined by an 
Ethics Advisory Board (EAB) established by the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research within the Department of Health, 
Education, and Welfare (Stem Cell History, 2011). Since then, the laws governing embryos and 
stem cells, and where funds will be directed has been a reflection of that period’s governing 
administrations. 
In 1980, President Ronald Reagan began a long lasting de facto moratorium which 
banned federal funding for embryo research for 13 years until 1993 when President William 
Clinton exercised his presidential executive order to lift the moratorium. This however did not 
last very long, as he reversed the order a year later in response to thousands of letters urging him 
to do so, even though the National Institute of Health (NIH) human embryonic research panel (a 
panel he created) recommended otherwise in regards to the “profound ethical and moral 
questions” raised by the subject (Clinton, 1994). President Clinton did however allow funding 
for research involving excess embryos created by in vitro fertilization that would not be used for 
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implantations. Nevertheless, the republican-led Congress felt they needed to intervene, and 
enacted the Dickey-Wicker Amendment, which stated that federal funding could not be used to 
support the creation of human embryos for research purposes (Genetics and Public Policy 
Center, 2011).  Specifically, the amendment prohibited federal money to be spent on research in 
which a human embryo would be destroyed, discarded, or knowingly subjected to risk of injury 
or death (Stem Cell History, 2011). 
After the discovery of human embryonic stem cells by James Thomson (1998), the NIH 
began to draft guidelines to support funding research using these cells, as they determined that 
ES cells did not meet the statutory definition of an embryo, therefore the Dickey-Wicker 
Amendment did not apply to them.  The NIH Guidelines were published in August 2000 
(National Institutes of Health Guidelines, 2000).  The guidelines recommended that funds be 
given to researchers using human ES cells so long as they were derived with private funds from 
frozen embryos from fertility clinics; the embryos must have been created for fertility treatment 
purposes and be in excess of the donor’s reproductive need; and the embryos must be obtained 
with the consent of the donor.  However, upon reading these guidelines, President George W. 
Bush enacted an executive policy stating that researchers could only use ES cell lines created 
before August 9, 2001 consisting of a supposed 60 stem cell lines believed to be available at the 
time (Bush, 2001), although only a handful of cell lines were realistically available (Agnew, 
2003). Difficulties encompassing embryonic stem cell research continued under President Bush’s 
two terms, as he constantly ignored emerging guidelines published by the National Academies of 
Science and the International Society for Stem Cell Research, and he vetoed two bills passed by 
Congress (Babington, 2006). 
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Hope for researchers came with the inauguration of President Barack Obama in 2009 as 
he immediately lifted his predecessor’s ban on federal funding for embryonic stem cell research, 
stating that the government needed to make “scientific decisions based on facts, not ideology” 
(Childs & Stark, 2009) which is where the government currently stands on the issue.  However, 
Obama’s policy remains rigorous, and diligently abides by the NIH Guidelines.  The embryos 
must be derived from excess embryos from reproductive clinics, with donor consent, and no 
embryos can be created solely for research purposes.  In light of promoting embryonic stem cell 
research, President Obama has also taken a firm position against human cloning as he believes it 
“dangerous, profoundly wrong, and has no place in our society, or any society” (CBS/AP, 2009) 
 
Stem Cell Laws for Individual US States 
While federal funding was unavailable for ES research for nearly a decade during the 
Bush administration, a few states took it upon themselves to fund their own scientists (Figure-2) 
allowing headway on the research, although at a reduced rate relative to what federal funding 
could have provided.  
New Jersey spearheaded this movement in early 2004, when its legislative branch passed 
a bill named S1909/A2840 which legalized the cloning of human embryos so that they can be 
developed during their temporary implantation in a womb and then harvested for medical 
research. They also pledged to assign $6.5 million to universities, non-profit and private research 
labs investigating ES stem cells to stimulate an influx of jobs in the growing industry (Scherer, 
2004).  Since then, the Garden State has awarded an extra $10 million in stem cell research 
grants in an attempt to “further…New Jersey’s position as a national research in stem cell 
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research” (Fineman, 2007).  It also approved $270 million in loans to build the Stem Cell 
Institute of New Jersey (Wadman, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: Stem Cell Legislation in the US by State.  (Specht & Hurt, 2005) 
 
The state of California was quick to follow later in November 2004, when they passed 
Proposition 71, an amendment to the Constitution of California which authorized the state to 
donate $3 billion in general obligation bonds (bonds usually used for developing state 
infrastructure) to stem cell research programs within the state (Hayden, 2008). Along with this, 
the California Institute for Regenerative Medicine (CIRM) was birthed to help decide where the 
California grants would be allocated, to establish regulatory standards for conducting stem cell 
research and to oversee the development of stem cell research and its related facilities in 
California (Legislative Analyst’s Office, 2004).  Following the installation of CIRM, a total of 
453 private and public research institutions in the state have benefited from more than $1.25 
billion in research grants (CIRM, 2011). While several other states such as Connecticut, Illinois, 
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Maryland, Massachusetts, New York, and Wisconsin followed California and New Jersey by 
making their own plans to donate a sum of nearly $3 billion over the next ten years, other states 
such as Louisiana and North Dakota have banned ES cell research (Figure-3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-2: Diversity of State Funding for Embryonic Stem Cell Research in the US.  (Wadman, 2008) 
 
 
Stem Cell Laws in Other Countries 
Looking back at Figure-1, it is apparent that the world is currently divided between 
allowing and prohibiting ES cell research. Interestingly, it can be noted that arguably the most 
powerful countries in the world (the five permanent members of the UN Security Council) 
(China, USA, Russia, United Kingdom, and France) all fully support the use of surplus embryos 
obtained from fertility clinics for research.  Adding in Brazil, Japan, and India (three additional   
major contributors to world economy and development) which are also in favor of ES cell 
research, these eight countries represent more than 3.4 billion people, about half of the world’s 
population!  Furthermore, these countries all obey a United Nations International Convention 
installed in February 2005 against human reproductive cloning, showing a clear divide between 
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working with excess embryos versus human reproductive cloning within these eight leading 
countries (Office of Legal Affairs, 2005).   However, many countries remain divided on whether 
to allow human therapeutic cloning to produce human ES cell lines from individual patients for 
treating the same patient with his own cells. 
As in the US between various states, much disagreement can also be found within the 
European Union which actually has no over-riding current regulations or laws concerning the 
research of stem cells, leaving its 25 member countries to decide legislation themselves. 
Currently, the continent is split on the matter with research on ES cells being permitted in 
Sweden, Finland, Belgium, Greece, Great Britain, Denmark, and the Netherlands, while being 
illegal in Germany, Austria, Italy, Ireland, and Portugal, reflecting the ethical, philosophical, and 
religious diversity found in the EU.  Although divided on the legalities of ES cell research, 
European courts recently ruled that no scientist working in the EU is permitted to obtain a patent 
on any method describing how to destroy human embryos, as the court fears it would hinder 
research and stifle commercial investment (Sample, 2011).  In Europe, many scientists feel that 
this is a step backwards for stem cell research, as techniques developed and paid for by 
Europeans will be used for free in other parts of the world. 
Serving Europe as their unofficial leader in stem cell research is Great Britain where the 
first successful mammalian clone, Dolly the sheep, was made in 1996 (Campbell et al., 1996; 
Ralston, 2008). The UK has been a major historical contributor to stem cell research, beginning 
in the 1980s when the British Parliament implemented a committee to recognize the ethical 
concerns of stem cell research and to recommend appropriate regulations.  This was followed in 
1990 by enactment of the Human Fertilization and Embryology Act which stated that any 
research conducted on embryos must be approved by the Human Fertilization and Embryo 
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Authority (FFEA), any embryos used must have been created in vitro, and the research on these 
cells must not exceed 14 days (EuroStemCell, 2007). These British stem cell policies have 
received much support from the public and as a result, researchers have benefitted from more 
than £220 million in funding in addition to the creation of a new £30 million stem cell center due 
to open in April 2012 to stimulate foreign investment in their biotech industry.  They also felt 
that a surge of funding would help prevent scientists from leaving the country to find work 
elsewhere (Neate, 2011). 
France and Germany have employed more conservative ES cell policies limiting their 
research development. France has traditionally been against using any embryos for research, but 
in 2004 a bioethics committee decided that scientists would have a five-year window of 
exception to their normal ban. This allowed researchers to use imported embryonic stem cells 
created in vitro only. Although there are signs of increasing openness to the subject in France, 
currently the country is at a stalemate with no consensus (UKSCI, 2009). Almost the polar 
opposite of the UK, Germany is known for having a stiff opposition to pro-embryo research.  In 
2002, the German Stem Cell Act was passed effectively banning the import or use of human 
embryonic stem cells unless strict criteria were met, in which case stem cell lines made before 
2002 could only be used.  Staunch hostility continued in 2004 when the German National Ethics 
Council (NER) demanded a global ban of embryonic cloning.  However, the German fight for 
embryonic research turned a new page in 2008 when the Bundestag (Lower House) amended the 
Act to allow scientists to use stem cell lines created before May 1
st
, 2007 (Ralston, 2008). 
China, often referred to as the “land of opportunity” for stem cell research, is known for 
the great flexibility the government uses when it comes to studying and using stem cells.  This 
flexibility stems from different ethical and cultural views (Barnes, 2006).  Some expatriate 
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scientists and biotech companies have moved their research to China in light of being able to 
work comfortably while using embryonic cell lines in both the laboratory and the clinic. The 
view of the Chinese stem cell community is that they have world-class expertise in the field, but 
also have a serious deficiency in the national infrastructure necessary to support the science.  
Specifically, government funding is limited as the Ministry of Science and Technology only 
issues a central budget that is divided evenly for “basic stem-cell research” and “applied stem-
cell research” for researchers to apply to.  Only an estimated $24 million was spent by the 
national government in the first five years of these projects, while the local governments of 
Beijing and Shanghai were reported to spend the same amount on research (Murray, 2006). 
Additionally, many researchers in the international scientific community have called Chinese 
policy makers too relaxed, as China is known for using stem-cell treatments without having 
performed conclusive clinical trials beforehand. Resultantly, on May 1
st
, 2009 a new set of 
guidelines were published by the Ministry of Health mandating that Chinese institutions which 
provide stem cell therapies must pass strict technical audits.  The audits must demonstrate the use 
of clinical-trials that show the safety and efficacy of treatments, include an approved ethics 
advisory board, and the researchers must have significant experience in the field (Stem Cell 
Transplantation Department, 2011). 
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PROJECT CONCLUSIONS 
 
 
 
Based on the research performed for this project, and their own personal observations, 
each author makes their own separate conclusions: 
 
DPW’s Conclusions 
 Based on the information presented in this study, I believe that more research in the stem 
cell field is needed to help ensure that these life saving techniques, which exploit the 
regenerative potency of stem cells, reach patients. Unfortunately we do not yet know enough 
about how these cells grow and function in the developed human body. As a result, the number 
of treatments for patients is currently very limited, and is generally only offered in a few clinical 
studies.  I feel as though the advancement of stem cell applications, especially for ES cells, has 
been greatly hindered because of the deep effect organized religion has on politics and laws.  
However, with newer political administrations across the globe, much advancement has been 
seen in the past decade with governments making “scientific decisions based on facts, not 
ideology” (Childs & Stark, 2009). This wide-spread support is extremely critical for ES cells, as 
they possess the greatest plasticity of all the stem cell forms and can offer the best solution to 
patients.  Although I strongly feel that ES cells should be scientist’s primary concern, I do not 
believe that embryos should be created solely for research purposes, and agree with the current 
US government’s stance on allowing surplus embryos created from IFV to be studied. 
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ED’s Conclusions 
Raised in a conservative Roman Catholic family, the concept of “respect for life” was 
instilled in me at a young age. Thankfully my interest in the life sciences also grew with me and I 
have had the chance to examine the embryonic stem cell debate from both scientific and 
theological perspectives.  I have come to the conclusion that the investigation of ESCs and the 
subsequent destruction of embryos for therapeutic and research purposes can be justified in our 
current situation. Thousands of embryos created for in vitro fertilization (IVF) treatments are 
discarded each year, and I personally feel that denying the scientific benefits of these already 
forsaken embryos is ignorant and wasteful. Regardless of whether the embryos are considered 
life, I believe it is more ethical to destroy them while extracting valuable stem cells than to 
simply destroy them as bulk medical waste.  For this reason, I fully support President Obama’s 
2009 executive order to lift the ban on stem cell research on surplus embryos from fertility 
treatments and support the resulting NIH standards for this research.   
 I do not claim to know at what moment life or ensoulment begin, but I believe that 
creating viable embryos solely for scientific research is an ethical concern since the morality of 
creating life to destroy it is questionable. I instead support other methods that supply pluripotent 
stem cells, like the induced pluripotency stem cell (iPS) techniques using genetic engineering to 
reverse the differentiation of adult stem cells. I am very much in favor of using adult stem cells 
for research in both their differentiated and undifferentiated states, because the isolation of these 
cells does not involve the destruction of a potential life.  Ideally we will discover an efficient, 
non-controversial way to isolate or create pluripotent stem cells, and continue to advance the 
applications of stem cell technology. 
 
